The Food and Drug Administration is convening a public workshop titled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th from 8:30pm to 4:30pm ET. The purpose of this workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic fibrosis (CF) and non-CF bronchiectasis. Stay informed and participate virtually by viewing the forum via webcast here.
FDA Workshop on Bronchiectasis Drug Development
Do you have Nontuberculous
Mycobacterial (NTM) Pulmonary Disease?
220,000
ESTIMATED CASES
OF NTM IN THE US
IN 2020
8.2 %
THE RISE IN THE
NUMBER OF NTM CASES
EACH YEAR
2.8m
ANTIBIOTIC-
RESISTANT INFECTIONS
IN THE US EACH YEAR
